Advertisement
Australia markets close in 1 minute

  • ALL ORDS

    7,809.30
    -89.60 (-1.13%)
     

  • ASX 200

    7,559.00
    -83.10 (-1.09%)
     

  • AUD/USD

    0.6400
    -0.0026 (-0.40%)
     

  • OIL

    84.44
    +1.71 (+2.07%)
     

  • GOLD

    2,394.10
    -3.90 (-0.16%)
     

  • Bitcoin AUD

    96,827.59
    +1,283.35 (+1.34%)
     

  • CMC Crypto 200

    1,283.93
    -28.69 (-2.14%)
     

  • AUD/EUR

    0.6018
    -0.0013 (-0.22%)
     

  • AUD/NZD

    1.0882
    +0.0007 (+0.06%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,144.07
    -241.80 (-1.48%)
     

  • NIKKEI 225

    37,124.07
    -955.63 (-2.51%)
     

Shattuck Labs to Present at TIGIT Therapies Digital Summit 2021

Shattuck Labs, Inc.
·2-min read

AUSTIN, TX and DURHAM, NC, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced its presentation at the TIGIT Therapies Digital Summit 2021 being held virtually December 7 – 9, 2021.

Presentation Details
Presentation Title: LIGHTing the Way for TIGIT Blockade in CPI Refractory Tumors
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: December 9, 2021
Time: 9:30 a.m. EST
Location: https://tigit-therapies.com/

The presentation will be available for download on the Events & Presentations section of the company’s website and also will be available to registered participants of the TIGIT Therapies Digital Summit 2021.

About Shattuck Labs, Inc.

Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in two Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

ADVERTISEMENT

Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com